Free Trial

Regeneron Pharmaceuticals Top Holdings and 13F Report (2026)

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals NASDAQ: REGN has filed 13-F forms with the SEC as an investor. Regeneron Pharmaceuticals is itself a publicly traded company. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. For more information on Regeneron Pharmaceuticals stock, visit the Regeneron Pharmaceuticals stock profile here.

Investment Activity

  • Regeneron Pharmaceuticals has $47.88 million in total holdings as of March 31, 2026.
  • Regeneron Pharmaceuticals owns shares of 2 different stocks, but just 1 company or ETF makes up 80% of its holdings.
  • This quarter, Regeneron Pharmaceuticals has purchased 2 new stocks and bought additional shares in 0 stocks.
  • Regeneron Pharmaceuticals sold shares of 0 stocks and completely divested from 0 stocks this quarter.

Largest Holdings

Adicet Bio
$412,080

Sector Allocation Over Time

Map of 500 Largest Holdings ofRegeneron Pharmaceuticals

 
 
Selling
 
 
Neutral
 
 
Buying
Issuer NameHoldings ValueApproximate Purchase/SaleChange in SharesShares Held% of PortfolioSector
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$47,472,3960.0%3,702,99599.1%Medical
Adicet Bio, Inc. stock logo
ACET
Adicet Bio
$412,0800.0%60,5110.9%Medical

Showing largest 100 holdings. View all holdings.
SEC Filings and Trading Data